Peptide Database
Showing 11 of 58 peptides
| Category | FDA Status | |||
|---|---|---|---|---|
| SemaglutideWeight loss, type 2 diabetes, cardiovascular risk reduction | Weight Loss | Approved | Approved | 284 trial pubs713 registered4,535 PubMed references |
| TirzepatideWeight loss, type 2 diabetes, dual GIP/GLP-1 agonist | Weight Loss | Approved | Approved | 122 trial pubs254 registered1,942 PubMed references |
| RetatrutideWeight loss, triple agonist (GLP-1/GIP/glucagon) | Weight Loss | Phase III | Not Approved | 6 trial pubs33 registered133 PubMed references |
| TesamorelinVisceral fat reduction, growth hormone deficiency, lipodystrophy | Growth HormoneWeight Loss | Approved | Approved | 23 trial pubs24 registered87 PubMed references |
| CagrilintideWeight loss, amylin analog, combined with semaglutide | Weight Loss | Phase III | Not Approved | 8 trial pubs42 registered72 PubMed references |
| AOD-9604Fat metabolism, weight loss, cartilage repair | Weight Loss | Preclinical | Category 2 | 0 trial pubs0 registered11 PubMed references |
| MazdutideWeight loss, dual GLP-1/glucagon agonist, Chinese-developed obesity drug | Weight Loss | Approved | Investigational | 6 trial pubs34 registered38 PubMed references |
| SurvodutideWeight loss, MASH/NASH liver disease, dual GLP-1/glucagon agonist | Weight Loss | Phase III | Investigational | 7 trial pubs24 registered60 PubMed references |
| TesofensineWeight loss, triple monoamine reuptake inhibitor, appetite suppression | Weight Loss | Phase II | Investigational | 11 trial pubs13 registered51 PubMed references |
| LiraglutideWeight loss, type 2 diabetes, cardiovascular protection | Weight Loss | Approved | Approved | 606 trial pubs512 registered5,328 PubMed references |
| 5-amino-1MQFat loss, metabolic health, NNMT inhibition | Weight Loss | Animal | Not Approved | 0 trial pubs0 registered4 PubMed references |